Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report) traded up 0.4% on Wednesday . The company traded as high as $0.49 and last traded at $0.48. 12,216 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 62,303 shares. The stock had previously closed at $0.47.
Entero Therapeutics Stock Up 0.4 %
The firm has a 50 day moving average price of $0.56 and a 200-day moving average price of $0.51.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
See Also
- Five stocks we like better than Entero Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- 2 Stocks Riding the Dominance of America’s Natural Gas Exports
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Buffett’s on the Sidelines – Should You Follow?
- What Are Some of the Best Large-Cap Stocks to Buy?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
